share_log

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

Truist Securities維持對Allogene Therapeutics的買入,將目標股價
Benzinga ·  2023/07/12 11:31

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $20 to $18.

Truist Securities分析師Asthika Goonewardene維持Allogene Therapeutics(納斯達克股票代碼:ALLO)的買入,並將目標股價從20美元下調至18美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論